« Back
Home /
Canertinib

Canertinib

Item no.	M1943-1g
Manufacturer	AbMole
CASRN	267243-28-7
Amount	1g
Category	Oncology Neuroscience Metabolism Diabetes Cholesterol & Lipid Metabolism Regulation of Appetite Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	>99.0%
Citations	Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. Jänne PA, et al . J Clin Oncol. 2007 Sep 1,25(25):3936-44. PMID: 17761977 . Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Calvo E, et al . Clin Cancer Res. 2004 Nov 1,10(21):7112-20. PMID: 15534081 . CI-1033, a pan-erbB tyrosine kinase inhibitor. Slichenmyer WJ, et al . Semin Oncol. 2001 Oct,28(5 Suppl 16):80-5. PMID: 11706399 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CI-1033, PD-183805
Similar products	Canertinib, CI-1033, PD-183805
Available
Molecular Weight	485, 94
Solubility	Ethanol ≥ 7 mg/mL
Bioactivity information	Canertinib (CI-1033) is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM).

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1943-1g-safety-datasheet.pdf